Every market. Every requirement.

Germany is Cannvera's primary target market and Europe's largest legal cannabis market. The CanG (April 2024) legalized adult-use cannabis and established non-profit social clubs, while the pharmaceutical channel has seen 155% growth. Germany represents 40–50% of all EU cannabis imports. Cannvera serves both pharmaceutical and adult-use buyers.

Czech Republic is both an active cannabis processing hub and an emerging adult-use market. From January 2026, Czech law permits adults (21+) to possess up to 100g and cultivate up to three plants. Commercial sales remain prohibited. Cannvera serves the Czech pharmacy channel and qualified adult-use buyers.

Austria operates a licensed medical cannabis import framework similar to Germany. Austrian pharmacies and licensed distributors require GMP-certified supply with full documentation packages.

Switzerland operates outside the EU regulatory framework but maintains a medical cannabis import system. The Swiss market is bifurcated between medical (Swissmedic-regulated) and wellness (CBD < 1% THC) channels.

Poland legalized medical cannabis imports in 2017 and has seen steady growth in licensed pharmacy procurement. The market is less mature than Germany but growing rapidly, with significant unmet demand.

Post-Brexit, the UK operates its own cannabis import framework under the MHRA. Medical cannabis prescriptions have grown significantly since legalization in 2018, creating demand for GMP-certified supply.

South Africa is an active market for Cannvera. The country has a growing licensed cannabis industry with increasing demand for internationally sourced, GMP-certified product across both medical and wellness segments.

Israel is one of the world's most established medical cannabis research and production hubs. Cannvera has deep roots in the Israeli cannabis industry and sources premium genetics and processed product from Israeli GACP/GMP-certified partners for export to licensed international markets.

Australia is one of the world's most established medical cannabis markets. Cannvera has supplied Australian buyers and understands TGA documentation requirements. The market is characterized by high quality standards and strong price tolerance for premium, fully documented product.